urothelial cancer, Bladder cancer, muscle invasive bladder cancer
Conditions
Brief summary
18months overallsurvival (OS)
Detailed description
OS in PD-L1 positive and PD-L1 negative tumors, in patients with visceral versus non-visceral metastases, in patients with CR/PR as best response to chemotherapy versus SD, and in retreated patients. PFS in PD-L1 positive and PD-L1 negative tumors, and in retreated patients. ORR per RECIST 1.1 in retreated patients. Duration ofresponse. Disease control (defined as complete response, partial response, non—complete response or non-progressive disease, orstable disease at 24 weeks after initi
Interventions
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 18months overallsurvival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| OS in PD-L1 positive and PD-L1 negative tumors, in patients with visceral versus non-visceral metastases, in patients with CR/PR as best response to chemotherapy versus SD, and in retreated patients. PFS in PD-L1 positive and PD-L1 negative tumors, and in retreated patients. ORR per RECIST 1.1 in retreated patients. Duration ofresponse. Disease control (defined as complete response, partial response, non—complete response or non-progressive disease, orstable disease at 24 weeks after initi | — |
Countries
Netherlands
Outcome results
None listed